12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane nab-paclitaxel: Preliminary Phase I/II data

Preliminary data from the Phase I portion of an open-label, dose-escalation, U.S. Phase I/II trial in 18 evaluable patients who previously failed Bacillus Calmette-Guerin (BCG) therapy showed that Abraxane produced 5 complete responses at week 12. Abraxane was well tolerated...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >